Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)

Vyome (NASDAQ:HIND) and Perspective Therapeutics (NASDAQ:CATX) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

22.1% of Vyome shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Comparatively, 3.7% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Vyome has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Vyome and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-423.39%	-166.02%
Perspective Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Vyome and Perspective Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1	0	2	0	2.33
Perspective Therapeutics	0	0	3	0	3.00

Vyome currently has a consensus price target of $15.00, indicating a potential upside of 224.68%. Perspective Therapeutics has a consensus price target of $10.00, indicating a potential upside of 274.53%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than Vyome.

Earnings & Valuation

This table compares Vyome and Perspective Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$8.01 million	3.25	-$7.13 million	($125.20)	-0.04
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-2.97

Perspective Therapeutics has lower revenue, but higher earnings than Vyome. Perspective Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Summary

Perspective Therapeutics beats Vyome on 9 of the 12 factors compared between the two stocks.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.